Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “overweight” rating reaffirmed by stock analysts at Piper Jaffray Companies in a research note issued on Thursday, The Fly reports. They presently have a $14.71 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $188.00. Piper Jaffray Companies’ price target would suggest a potential downside of 87.93% from the stock’s previous close.

Several other research firms have also recently commented on ALNY. B. Riley began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $150.00 target price for the company. FBR & Co began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $150.00 target price for the company. Goldman Sachs Group, Inc. (The) upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $62.00 to $163.00 in a research note on Monday, October 2nd. Chardan Capital restated a “buy” rating and issued a $124.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Finally, Jefferies Group LLC raised their target price on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $100.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the business posted ($1.05) EPS. The firm’s revenue was up 82.9% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/02/alnylam-pharmaceuticals-inc-alny-receives-overweight-rating-from-piper-jaffray-companies.html.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares in the company, valued at $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold a total of 195,797 shares of company stock worth $22,435,072 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in ALNY. BlackRock Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after purchasing an additional 4,732,617 shares during the last quarter. FMR LLC boosted its stake in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after purchasing an additional 759,295 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $53,226,000. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 305.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 508,852 shares of the biopharmaceutical company’s stock worth $40,586,000 after purchasing an additional 383,214 shares during the last quarter. 94.39% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

The Fly

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.